Physician profile
Harsh Chawla
NPI 1003070350
$4,735.05
in general payments reported to CMS, 2019-2025
22 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.71 · 2020: $282 · 2021: $484 · 2022: $794 · 2023: $697 · 2024: $478 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,597 · Travel and Lodging: $1,373 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,597.06 |
| Travel and Lodging | $1,372.74 |
| Education | $111.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,372.74 | 2025 | Monarch |
| Astrazeneca Pharmaceuticals LP | $1,330.41 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $718.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.32 | 2019-2024 | Ofev |
| Advanced Respiratory, INC | $166.79 | 2019-2021 | |
| Genzyme Corporation | $112.37 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $109.83 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $101.51 | 2021-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $84.22 | 2025 | Zerbaxa |
| Resmed Corp | $66.77 | 2023 | |
| Olympus Corporation of The Americas | $60.00 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.12 | 2021-2024 | Lifevest |
| Baxter Healthcare | $38.40 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $35.24 | 2024 | Lumryz |
| Philips North America LLC | $34.75 | 2024 | (Ak6) Vest Therapy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $30.41 | 2020-2021 | |
| Genentech USA, INC. | $21.67 | 2020 | |
| Grifols USA, LLC | $20.48 | 2024 | Prolastin-C Liquid |
| Idorsia Pharmaceuticals US INC | $17.87 | 2023 | Quviviq |
| Polarityte, INC. | $17.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.84 | 2022 | |
| Itamar Medical INC | $15.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.